70
Participants
Start Date
February 29, 2016
Primary Completion Date
August 31, 2016
Study Completion Date
December 31, 2016
PA101B
40 mg PA101B administered via inhalation twice daily for 7 weeks
Placebo
Matching placebo administered via inhalation twice daily for 7 weeks
Ridgewood Dialysis Center, Ridgewood
Brookview Hills Research Associates LLC, Winston-Salem
Pines Clinical Research, Inc., Pembroke Pines
Genesis Clinical Research, Tampa
Southeast Renal Research Institute, Chattanooga
Fresenius Medical Care of Evergreen Park, Evergreen Park
US Renal Care, Pine Bluff
Boise Kidney and Hypertension Institute, Meridian
Arizona Kidney Disease and Hypertension Center, Phoenix
Renal Medicine Associates, Albuquerque
US Renal Care, Gallup
Valley Renal Medical Group, Northridge
North America Research Institute, San Dimas
Lead Sponsor
Patara Pharma
INDUSTRY